Total Payments
$459,299
2024 Payments
$8,958
Companies
22
Transactions
653
Medicare Patients
3,917
Medicare Billing
$800,199
Payment Breakdown by Category
Other$372,195 (81.0%)
Travel$57,937 (12.6%)
Food & Beverage$20,324 (4.4%)
Consulting$8,135 (1.8%)
Education$709.36 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $274,536 | 115 | 59.8% |
| Honoraria | $97,659 | 48 | 21.3% |
| Travel and Lodging | $57,937 | 261 | 12.6% |
| Food and Beverage | $20,324 | 219 | 4.4% |
| Consulting Fee | $8,135 | 4 | 1.8% |
| Education | $709.36 | 6 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $163,405 | 211 | $0 (2024) |
| Melinta Therapeutics, LLC | $147,640 | 220 | $0 (2024) |
| The Medicines Company | $77,062 | 118 | $0 (2017) |
| TETRAPHASE PHARMACEUTICALS, INC. | $25,741 | 21 | $0 (2019) |
| Ferring Pharmaceuticals Inc. | $17,073 | 20 | $0 (2023) |
| La Jolla Pharmaceutical Company | $16,222 | 19 | $0 (2024) |
| Astellas Pharma US Inc | $7,957 | 14 | $0 (2024) |
| Theravance Biopharma Inc. | $2,529 | 3 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $310.16 | 3 | $0 (2018) |
| Allergan, Inc. | $242.98 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,958 | 16 | La Jolla Pharmaceutical Company ($4,796) |
| 2023 | $24,193 | 37 | Merck Sharp & Dohme LLC ($10,775) |
| 2022 | $15,967 | 20 | La Jolla Pharmaceutical Company ($6,987) |
| 2021 | $9,943 | 10 | Melinta Therapeutics, LLC ($3,260) |
| 2020 | $9,736 | 11 | Merck Sharp & Dohme Corporation ($9,516) |
| 2019 | $99,456 | 124 | Merck Sharp & Dohme Corporation ($53,506) |
| 2018 | $177,647 | 253 | Melinta Therapeutics, Inc. ($114,869) |
| 2017 | $113,401 | 182 | The Medicines Company ($77,062) |
All Payment Transactions
653 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $34.52 | General |
| Category: Infectious Diseases | ||||||
| 11/21/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Honoraria | Cash or cash equivalent | $2,242.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/21/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $134.77 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/24/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $26.35 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 05/28/2024 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 05/01/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $44.62 | General |
| Category: IMMUNOLOGY | ||||||
| 03/27/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Education | In-kind items and services | $51.00 | General |
| Category: ANTIBIOTIC | ||||||
| 03/27/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: ANTIFUNGALS | ||||||
| 02/21/2024 | Melinta Therapeutics, LLC | Vabomere (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,400.00 | General |
| Category: ANTIBIOTICS | ||||||
| 02/21/2024 | Melinta Therapeutics, LLC | Vabomere (Drug) | Travel and Lodging | Cash or cash equivalent | $276.18 | General |
| Category: ANTIBIOTICS | ||||||
| 02/21/2024 | Melinta Therapeutics, LLC | Vabomere (Drug) | Travel and Lodging | Cash or cash equivalent | $171.93 | General |
| Category: ANTIBIOTICS | ||||||
| 02/21/2024 | Melinta Therapeutics, LLC | Vabomere (Drug) | Food and Beverage | In-kind items and services | $102.09 | General |
| Category: ANTIBIOTICS | ||||||
| 02/07/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Honoraria | Cash or cash equivalent | $2,242.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/07/2024 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Food and Beverage | In-kind items and services | $127.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/31/2024 | Smith+Nephew, Inc. | COLLAGENASE SANTYL (Drug) | Food and Beverage | In-kind items and services | $24.19 | General |
| Category: Pharma Products | ||||||
| 01/30/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $32.86 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/29/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: Respiratory | ||||||
| 10/26/2023 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Education | In-kind items and services | $27.36 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/26/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: Infections and Infectious Diseases | ||||||
| 08/29/2023 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 06/28/2023 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Rezzayo, Vabomere | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: ANTIBIOTICS | ||||||
| 05/24/2023 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Honoraria | Cash or cash equivalent | $2,242.00 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 05/24/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: Infections and Infectious Diseases | ||||||
| 05/03/2023 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,255.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/26/2023 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,255.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 804 | 2,050 | $638,275 | $177,341 |
| 2022 | 6 | 898 | 2,570 | $748,975 | $184,303 |
| 2021 | 5 | 864 | 2,315 | $701,450 | $181,080 |
| 2020 | 7 | 1,351 | 3,147 | $947,725 | $257,474 |
Total Patients
3,917
Total Services
10,082
Medicare Billing
$800,199
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 235 | 924 | $323,400 | $85,030 | 26.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 270 | 757 | $189,250 | $46,021 | 24.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 52 | 111 | $44,400 | $18,921 | 42.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 120 | 127 | $50,800 | $17,116 | 33.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 85 | 86 | $23,675 | $8,573 | 36.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 42 | 45 | $6,750 | $1,680 | 24.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 199 | 931 | $325,850 | $75,990 | 23.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 373 | 1,297 | $324,250 | $72,948 | 22.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 101 | 107 | $42,800 | $16,436 | 38.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 144 | 146 | $40,175 | $15,457 | 38.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 65 | 72 | $10,800 | $2,253 | 20.9% |
| 99356 | Extended inpatient or observation hospital service, first hour | Facility | 2022 | 16 | 17 | $5,100 | $1,219 | 23.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 242 | 1,030 | $360,500 | $86,396 | 24.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 318 | 967 | $241,750 | $56,457 | 23.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 149 | 155 | $62,000 | $25,108 | 40.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 102 | 102 | $28,050 | $11,218 | 40.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 53 | 61 | $9,150 | $1,901 | 20.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 288 | 1,132 | $396,200 | $96,108 | 24.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 474 | 1,346 | $336,500 | $78,579 | 23.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 190 | 193 | $77,200 | $31,969 | 41.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 184 | 195 | $53,625 | $21,863 | 40.8% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 53 | 101 | $40,400 | $18,387 | 45.5% |
| 99356 | Prolonged inpatient or observation hospital service first hour | Facility | 2020 | 104 | 112 | $33,600 | $8,378 | 24.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 58 | 68 | $10,200 | $2,190 | 21.5% |
About Dr. Jason Sniffen, DO
Dr. Jason Sniffen, DO is a Infectious Disease healthcare provider based in Altamonte Springs, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1982604856.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jason Sniffen, DO has received a total of $459,299 in payments from pharmaceutical and medical device companies, with $8,958 received in 2024. These payments were reported across 653 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($274,536).
As a Medicare-enrolled provider, Sniffen has provided services to 3,917 Medicare beneficiaries, totaling 10,082 services with total Medicare billing of $800,199. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Altamonte Springs, FL
- Active Since 07/21/2005
- Last Updated 10/17/2013
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1982604856
Products in Payments
- ZERBAXA (Drug) $75,095
- Baxdela (Drug) $62,150
- ZINPLAVA (Biological) $43,400
- VABOMERE (Drug) $42,482
- ORBACTIV (Drug) $34,224
- DIFICID (Drug) $32,525
- Xerava (Drug) $25,741
- Vabomere (Drug) $21,634
- XERAVA (Drug) $11,427
- REBYOTA (Biological) $10,768
- Orbactiv (Drug) $8,479
- Cresemba (Drug) $5,969
- XACDURO (Drug) $4,773
- RECARBRIO (Drug) $4,130
- Kimyrsa (Drug) $3,110
- SIVEXTRO (Drug) $2,872
- VIBATIV (Drug) $2,529
- MINOCIN IV (Drug) $239.76
- JARDIANCE (Drug) $235.40
- AVYCAZ (Drug) $224.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Altamonte Springs
Dr. Juan Diaz, D.o, D.O
Infectious Disease — Payments: $1.1M
Infectious Disease $1.1M
Christopher Cooper, Md, MD
Infectious Disease — Payments: $373,256
Infectious Disease $373,256
Fernando Alvarado, Md, MD
Infectious Disease — Payments: $16,125
Infectious Disease $16,125
Javier Marinez, Md, MD
Infectious Disease — Payments: $7,961
Infectious Disease $7,961
Dr. Anibal Maldonado, M.d, M.D
Infectious Disease — Payments: $4,049
Infectious Disease $4,049
Joseph Katta, Do, DO
Infectious Disease — Payments: $2,143
Infectious Disease $2,143